Prelude Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
3analysts covering
FY EPS (est.)
-$0.54next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release (Estimated) | 12 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Marketable Securities Quarterly84.8MTarget: Sufficient to fund operations into Q2 2028 (including subsequent $90M offering proceeds)
Quarterly Research and Development (R&D) Expenses Quarterly13.6MTarget: Disciplined cost management following the pause of SMARCA2 clinical trials
Quarterly Net Loss Quarterly10.4MTarget: Narrowing loss compared to prior periods ($32.1M in Q1 2025)
Watch Items
- PRT13722 KAT6A Degrader IND Filing and Phase 1 InitiationTrigger: IND filing expected by mid-2026; Phase 1 study initiation expected in 2H 2026Action: Monitor regulatory clearance and first-in-human dosing milestones for ER+ breast cancer patients.
- PRT12396 Mutant-Selective JAK2V617F Inhibitor Phase 1 EnrollmentTrigger: Ongoing enrollment in patients with polycythemia vera (PV) and myelofibrosis (MF)Action: Track clinical progress and potential opt-in decisions or milestone triggers under the exclusive option agreement with Incyte.
- Cash Burn Rate and Runway SustainabilityTrigger: Quarterly operating cash burn relative to the combined ~$174.8M capital baseAction: Evaluate capital allocation efficiency and potential non-dilutive funding or partnership expansions.
Research as of 19 Jun 2026